Abstract

HIV-1 must replicate in cells that are equipped to defend themselves from infection through intracellular innate immune systems. HIV-1 evades innate immune sensing through encapsidated DNA synthesis and encodes accessory genes that antagonize specific antiviral effectors. Here we show that both particle associated, and expressed HIV-1 Vpr, antagonize the stimulatory effect of a variety of pathogen associated molecular patterns by inhibiting IRF3 and NF-κB nuclear transport. Phosphorylation of IRF3 at S396, but not S386, was also inhibited. We propose that, rather than promoting HIV-1 nuclear import, Vpr interacts with karyopherins to disturb their import of IRF3 and NF-κB to promote replication in macrophages. Concordantly, we demonstrate Vpr dependent rescue of HIV-1 replication in human macrophages from inhibition by cGAMP, the product of activated cGAS. We propose a model that unifies Vpr manipulation of nuclear import and inhibition of innate immune activation to promote HIV-1 replication and transmission.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Hataf Khan

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  2. Rebecca P Sumner

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  3. Jane Rasaiyaah

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Choon Ping Tan

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  5. Maria Teresa Rodriguez-Plata

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    Maria Teresa Rodriguez-Plata, Maria Teresa Rodriguez-Plata is affiliated with Black Belt TX Ltd. The author has no financial interests to declare..
  6. Chris Van Tulleken

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  7. Douglas Fink

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  8. Lorena Zuliani-Alvarez

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4682-4043
  9. Lucy Thorne

    Division of Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  10. David Stirling

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  11. Richard S B Milne

    Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  12. Greg J Towers

    Infection and Immunity, University College London, London, United Kingdom
    For correspondence
    g.towers@ucl.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7707-0264

Funding

Wellcome Trust (Senior Biomedical Research Fellowship)

  • Greg J Towers

H2020 European Research Council (Advanced Grant HIVinnate)

  • Greg J Towers

Medical Research Council (PhD studentship)

  • Hataf Khan

Medical Research Council (Clinical training fellowship)

  • Chris Van Tulleken

Wellcome Trust (Collaborative Award)

  • Greg J Towers

National Institute of Health Research (University College London Hospitals Biomedical Research Centre)

  • Greg J Towers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This study was approved by the UCL/UCLH Committees on the Ethics of Human Research, Committee Alpha reference (06/Q0502/92). All participants provided written informed consent and consent for publication.

Reviewing Editor

  1. John W Schoggins, University of Texas Southwestern Medical Center, United States

Version history

  1. Received: July 7, 2020
  2. Accepted: December 9, 2020
  3. Accepted Manuscript published: December 10, 2020 (version 1)
  4. Accepted Manuscript updated: December 12, 2020 (version 2)
  5. Version of Record published: December 24, 2020 (version 3)

Copyright

© 2020, Khan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,313
    Page views
  • 342
    Downloads
  • 19
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hataf Khan
  2. Rebecca P Sumner
  3. Jane Rasaiyaah
  4. Choon Ping Tan
  5. Maria Teresa Rodriguez-Plata
  6. Chris Van Tulleken
  7. Douglas Fink
  8. Lorena Zuliani-Alvarez
  9. Lucy Thorne
  10. David Stirling
  11. Richard S B Milne
  12. Greg J Towers
(2020)
HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF- κB/IRF3 nuclear transport
eLife 9:e60821.
https://doi.org/10.7554/eLife.60821

Further reading

    1. Cell Biology
    2. Microbiology and Infectious Disease
    Heledd Davies, Hugo Belda ... Moritz Treeck
    Tools and Resources

    Reverse genetics is key to understanding protein function, but the mechanistic connection between a gene of interest and the observed phenotype is not always clear. Here we describe the use of proximity labeling using TurboID and site-specific quantification of biotinylated peptides to measure changes to the local protein environment of selected targets upon perturbation. We apply this technique, which we call PerTurboID, to understand how the P. falciparum exported kinase, FIKK4.1, regulates the function of the major virulence factor of the malaria causing parasite, PfEMP1. We generated independent TurboID fusions of 2 proteins that are predicted substrates of FIKK4.1 in a FIKK4.1 conditional KO parasite line. Comparing the abundance of site-specific biotinylated peptides between wildtype and kinase deletion lines reveals the differential accessibility of proteins to biotinylation, indicating changes to localization, protein-protein interactions, or protein structure which are mediated by FIKK4.1 activity. We further show that FIKK4.1 is likely the only FIKK kinase that controls surface levels of PfEMP1, but not other surface antigens, on the infected red blood cell under standard culture conditions. We believe PerTurboID is broadly applicable to study the impact of genetic or environmental perturbation on a selected cellular niche.

    1. Microbiology and Infectious Disease
    Rita M Meganck, Deanna Zhu ... Longping V Tse
    Short Report

    A hallmark of dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which is associated with deadly DENV secondary infection, complicates the identification of correlates of protection, and negatively impacts the safety and efficacy of DENV vaccines. Antibody-dependent enhancement is linked to antibodies targeting the fusion loop (FL) motif of the envelope protein, which is completely conserved in mosquito-borne flaviviruses and required for viral entry and fusion. In the current study, we utilized saturation mutagenesis and directed evolution to engineer a functional variant with a mutated FL (D2-FL), which is not neutralized by FL-targeting monoclonal antibodies. The FL mutations were combined with our previously evolved prM cleavage site to create a mature version of D2-FL (D2-FLM), which evades both prM- and FL-Abs but retains sensitivity to other type-specific and quaternary cross-reactive (CR) Abs. CR serum from heterotypic (DENV4)-infected non-human primates (NHP) showed lower neutralization titers against D2-FL and D2-FLM than isogenic wildtype DENV2 while similar neutralization titers were observed in serum from homotypic (DENV2)-infected NHP. We propose D2-FL and D2-FLM as valuable tools to delineate CR Ab subtypes in serum as well as an exciting platform for safer live-attenuated DENV vaccines suitable for naïve individuals and children.